A dynamic power prior for borrowing historical data in noninferiority trials with binary endpoint

Traditionally, noninferiority hypotheses have been tested using a frequentist method with a fixed margin. Given that information for the control group is often available from previous studies, it is interesting to consider a Bayesian approach in which information is “borrowed” for the control group to improve efficiency. However, construction of an appropriate informative prior can be challenging. In this paper, we consider a hybrid Bayesian approach for testing noninferiority hypotheses in studies with a binary endpoint. To account for heterogeneity between the historical information and the current trial for the control group, a dynamic P value–based power prior parameter is proposed to adjust the amount of information borrowed from the historical data. This approach extends the simple test‐then‐pool method to allow a continuous discounting power parameter. An adjusted α level is also proposed to better control the type I error. Simulations are conducted to investigate the performance of the proposed method and to make comparisons with other methods including test‐then‐pool and hierarchical modeling. The methods are illustrated with data from vaccine clinical trials.

[1]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[2]  M Nurminen,et al.  Comparative analysis of two rates. , 1985, Statistics in medicine.

[3]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[4]  Donald J. Schuirmann A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[5]  J. Heyse,et al.  Statistical Considerations for NonInferiority/Equivalence Trials in Vaccine Development , 2006, Journal of biopharmaceutical statistics.

[6]  Hiroshi Nishiyama,et al.  Introduction of "Points to Consider on Switching between Superiority and Non-inferiority" and "Guideline on the Choice of the Non-inferiority Margin" , 2006 .

[7]  Penny M Heaton,et al.  Concomitant Use of an Oral Live Pentavalent Human-Bovine Reassortant Rotavirus Vaccine With Licensed Parenteral Pediatric Vaccines in the United States , 2007, The Pediatric infectious disease journal.

[8]  Draft Guidance Guidance for Industry Non-Inferiority Clinical Trials , 2010 .

[9]  Muhtarjan Osman,et al.  Semiparametric Bayesian Testing Procedure for Noninferiority Trials with Binary Endpoints , 2011, Journal of biopharmaceutical statistics.

[10]  Bradley P Carlin,et al.  Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.

[11]  Ram C Tiwari,et al.  Bayesian Approach to Noninferiority Trials for Proportions , 2011, Journal of biopharmaceutical statistics.

[12]  Joseph G Ibrahim,et al.  Bayesian Design of Noninferiority Trials for Medical Devices Using Historical Data , 2011, Biometrics.

[13]  Bradley P Carlin,et al.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.

[14]  Fang Chen,et al.  Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.

[15]  Ram C Tiwari,et al.  Bayesian approach to the design and analysis of non‐inferiority trials for anti‐infective products , 2014, Pharmaceutical statistics.

[16]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[17]  T. Ng Noninferiority Testing in Clinical Trials : Issues and Challenges , 2014 .

[18]  G. Liu,et al.  Immunogenicity, Safety, and Tolerability of a Hexavalent Vaccine in Infants , 2015, Pediatrics.

[19]  Brian L. Wiens,et al.  Design and Analysis of Non-Inferiority Trials , 2020 .